{
  "abstract": "We report the case of a middle childhood boy diagnosed with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), who was resistant to initial steroid pulse therapy and plasma exchange but achieved long-term remission following rituximab (RTX) treatment. Over a 4-year follow-up, the patient experienced no relapse, serum anti-MOG antibodies were undetectable and steroids were successfully tapered and discontinued. This case highlights the potential efficacy of RTX not only as a relapse-preventing agent but also as an acute-phase therapy in paediatric-onset MOGAD.",
  "authors": [
    {
      "affiliations": [
        "Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"
      ],
      "name": "Norifumi Yokoyama"
    },
    {
      "affiliations": [
        "Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan",
        "Department of Pediatrics, Gifu University, Gifu, Gifu Prefecture, Japan"
      ],
      "name": "Aki Kawase"
    },
    {
      "affiliations": [
        "Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"
      ],
      "name": "Taichi Miyazaki"
    },
    {
      "affiliations": [
        "Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"
      ],
      "name": "Ikko Oshiro"
    }
  ],
  "title": "Rituximab as acute rescue therapy for paediatric MOGAD refractory to standard treatment",
  "uid": "8d1d3ab5-3ca9-50fe-8ec8-32af679dcbc7"
}